A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study

• Main Authors: Hildenbrand Florian F, Fauchère Ivan, Huber Lars C, Keusch Stephan, Speich Rudolf, Ulrich Silvia
• Format: Article
• Language: English
• Published: BMC 2012-09-01
• Series: Respiratory Research
• Subjects: Chronic thromboembolic pulmonary hypertension; Heart rate; Prognosis; Pulmonary hypertension; Pulmonary arterial hypertension
• Online Access: http://respiratory-research.com/content/13/1/76

<p>Abstract</p> <p>Background</p> <p>A low resting heart rate (HR) is prognostically favourable in healthy individuals and in patients with left heart disease. In this study we investigated the impact of HR at diagnosis on long-term outcome in patients with differently classified precapillary pulmonary hypertension (pPH).</p> <p>Methods</p> <p>pPH patients diagnosed as pulmonary arterial (PAH) or inoperable chronic thromboembolic pulmonary hypertension (CTEPH) were registered and regularly followed at our centre Baseline characteristics and events defined as either death or lung transplantation were noted. The prognostic value of HR was analysed using Kaplan Meier estimates, live tables and Cox regression.</p> <p>Results</p> <p>206 patients with PAH (148) and inoperable CTEPH (58) were included. The median HR was 82 bpm. pPH with a HR below 82 bpm had a significantly longer overall event-free survival (2409 vs.1332 days, p = .000). This advantage was similarly found if PAH and CTEPH were analysed separately. Although a lower HR was associated with a better hemodynamic and functional class, HR was a strong and independent prognostic marker for transplant free survival even if corrected for age, sex, hemodynamics and functional status.</p> <p>Conclusion</p> <p>We show that resting HR at diagnosis is a strong and independent long-term prognostic marker in PAH and CTEPH. Whether reducing HR by pharmacological agents would improve outcome in pPH has to be assessed by future trials with high attention to safety.</p>